Imura Yoshinori, Naka Norifumi, Outani Hidetatsu, Yasui Hirohiko, Takenaka Satoshi, Hamada Ken-ichiro, Ozaki Ritsuro, Kaya Mitsunori, Yoshida Ken-ichi, Morii Eiichi, Myoui Akira, Yoshikawa Hideki
Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
BMC Res Notes. 2013 Aug 1;6:305. doi: 10.1186/1756-0500-6-305.
Whereas we can use several human epithelioid sarcoma (ES) cell lines for basic and preclinical research, an angiomatoid ES cell line has not been reported to date. We have treated a case of an angiomatoid ES developing in the right upper extremity of a 67-year-old man.
An angiomatoid ES cell line, Asra-EPS was newly established and characterized for its morphology, growth rate and chromosomal analysis. Tumorigenicity of Asra-EPS cells was also analyzed in athymic nude mice.
Asra-EPS cells were round, polygonal or spindle-shaped with an abundant cytoplasm and have been maintained continuously in vitro for over 150 passages during more than 15 months. These cells secreted cancer antigen 125 (CA 125), interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) into the culture medium. Asra-EPS cells were tumorigenic when implanted in nude mice with tumors reaching a volume of 1000 mm3 at around 50 days. Histological features of tumors formed in mice were essentially the same as those of the original tumor, exhibiting a multinodular proliferation of eosinophilic epithelioid and spindle-shaped cells with prominent areas of hemorrhage and blood-filled cystic spaces strikingly corresponding to the potential of hemorrhagic cyst formation in the original tumor. They showed immunopositive staining for cytokeratins (AE1/AE3 and CAM5.2), epithelial membrane antigen (EMA), vimentin, CD31, CD34 and CA 125, but negative for integrase interactor 1 (INI-1) and factor VIII-related antigen.
The established cell line represents a biologically relevant new tool to investigate the molecular pathology of human angiomatoid ES and to evaluate the efficacy of novel therapeutics both in vitro and in vivo.
虽然我们可以使用多种人类上皮样肉瘤(ES)细胞系进行基础研究和临床前研究,但迄今为止尚未报道过血管样ES细胞系。我们诊治了一名67岁男性右上肢发生的血管样ES病例。
新建立了一种血管样ES细胞系Asra-EPS,并对其形态、生长速率和染色体分析进行了表征。还在无胸腺裸鼠中分析了Asra-EPS细胞的致瘤性。
Asra-EPS细胞呈圆形、多边形或梭形,细胞质丰富,在体外连续培养超过15个月,传代超过150次。这些细胞向培养基中分泌癌抗原125(CA 125)、白细胞介素-6(IL-6)和血管内皮生长因子(VEGF)。将Asra-EPS细胞植入裸鼠后具有致瘤性,约50天时肿瘤体积达到1000 mm³。小鼠体内形成的肿瘤组织学特征与原发肿瘤基本相同,表现为嗜酸性上皮样和梭形细胞的多结节增殖,有明显的出血区和充满血液的囊性间隙,与原发肿瘤中出血性囊肿形成的可能性显著对应。它们对细胞角蛋白(AE1/AE3和CAM5.2)、上皮膜抗原(EMA)、波形蛋白、CD31、CD34和CA 125呈免疫阳性染色,但对整合酶相互作用因子1(INI-1)和因子VIII相关抗原呈阴性。
所建立的细胞系是一种生物学相关的新工具,可用于研究人类血管样ES的分子病理学,并在体外和体内评估新型治疗方法的疗效。